Glenmark Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹16,983cr+27.5% on FY25
EBITDA: ₹4,572cr+94.5% on FY25
Net profit: ₹1,362cr+30.1% on FY25
EPS: ₹48.26+30.0% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	17,737	16,983	13,322	11,813	12,990	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	500	461	114	840	317
	18,236	17,443	13,435	12,653	13,307
	2,830	2,961	3,001	3,158	3,594
	2,476	2,397	1,566	1,451	1,268
	−328	−611	−214	−196	−325
	3,750	3,578	3,022	2,868	2,781
	204	209	207	516	350
	617	573	486	582	611
	4,212	4,085	3,595	3,336	3,394
	13,761	13,192	11,663	11,716	11,673
	4,797	4,572	2,351	1,195	2,278
	4,180	3,999	1,865	613	1,667
Profit
	4,475	4,251	1,772	937	1,634
	−1,943	−2,266	−373	−901	−766
	2,533	1,985	1,399	36.5	868
	778	676	382	1,116	567
	−43.2	−53.7	−30.3	752	−75.9
	735	623	352	1,867	491
	1,798	1,362	1,047	−1,434	377
	1,798	1,362	1,047	−1,831	377
	0.0	0.0	0.0	397	0.0
	353	414	64.2	−65.6	154
	2,151	1,776	1,111	−1,499	531
	1,496	0.1	1,047	−1,502	—
	301	1,362	0.0	68.1	0.0
Per share
	₹63.71	₹48.26	₹37.11	−₹53.22	₹10.53
	₹63.69	₹48.24	₹37.10	−₹53.22	₹10.53
Continuing & discontinued operations
	0.0	0.0	0.0	533	0.0
	0.0	0.0	0.0	135	0.0
Other comprehensive income — detail
	353	414	64.2	—	—
	−9.5	−9.4	−12.0	−21.9	16.1
	2.4	2.4	−3.8	—	—
	—	—	—	−4.3	2.2
	426	483	86.7	−39.9	185
	61.1	57.1	14.4	—	—
	—	—	—	8.0	45.2
	1,661	0.1	1,111	−1,566	—
	490	1,776	0.0	67.2	—
Per share — as-filed variants
	₹63.71	₹48.26	₹37.11	−₹67.30	₹10.53
	₹63.69	₹48.24	₹37.10	−₹67.30	₹10.53
	₹0.00	₹0.00	₹0.00	₹14.08	₹0.00
	₹0.00	₹0.00	₹0.00	₹14.08	₹0.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	12,759	12,235	8,968	7,400	8,453
	71.9%	72.0%	67.3%	62.6%	65.1%
Adjusted (ex-exceptional items) — derived
	4,475	4,251	1,772	937	1,634
	−1,943	−2,266	−373	−901	−766
	3,177	2,917	1,326	−1,073	710
	₹112.59	₹103.36	₹47.00	−₹39.84	₹19.82

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLENMARK₹2,300.00

Glenmark Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDRREDDY LUPIN ALKEM BIOCON MANKIND LAURUSLABS FORTIS AUROPHARMAMcap ₹64,906 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	12,990.1	11,813.1	13,321.7	16,982.5	17,736.6
Other Income	316.8	840.0	113.7	460.6	499.9
Total Income	13,306.9	12,653.1	13,435.5	17,443.1	18,236.5
Expenses
+ Cost of Materials Consumed	3,593.8	3,157.8	3,001.3	2,961.5	2,830.1
+ Purchases of Stock-in-Trade	1,268.3	1,451.2	1,566.0	2,396.6	2,476.1
+ Changes in Inventories	-325.1	-195.6	-213.9	-610.6	-328.4
+ Employee Benefit Expense	2,781.0	2,868.1	3,022.1	3,577.9	3,749.8
+ Finance Costs	349.6	516.0	207.1	208.7	204.5
+ Depreciation & Amortisation	611.3	581.9	486.0	573.5	616.7
+ Other Expenses	3,393.8	3,336.3	3,595.0	4,084.8	4,212.4
Total Expenses	11,672.6	11,715.6	11,663.4	13,192.3	13,761.1
EBITDA	2,278.4	1,195.3	2,351.4	4,572.4	4,796.7
EBIT	1,667.1	613.4	1,865.4	3,998.9	4,180.0
Profit
PBT before Exceptional Items	1,634.3	937.5	1,772.0	4,250.8	4,475.4
+ Exceptional Items	-765.9	-901.0	-372.8	-2,266.1	-1,942.9
Pretax Income	868.5	36.5	1,399.2	1,984.7	2,532.6
+ Current Tax	566.9	1,115.6	382.3	676.5	778.0
+ Deferred Tax	-75.9	751.8	-30.3	-53.7	-43.2
Tax Expense	491.1	1,867.3	352.1	622.8	734.8
Net Income	377.4	-1,433.5	1,047.1	1,362.0	1,797.8
+ Net Income — Continuing Ops	377.4	-1,830.9	1,047.1	1,362.0	1,797.8
+ Net Income — Discontinued Ops	0.0	397.3	0.0	0.0	0.0
+ Other Comprehensive Income	153.7	-65.6	64.2	414.4	353.5
Total Comprehensive Income	531.1	-1,499.1	1,111.3	1,776.3	2,151.3
Net Income to Common	—	-1,501.7	1,047.1	0.1	1,496.4
Minority Interest	0.0	68.1	0.0	1,361.9	301.4
Per Share
Basic EPS	10.53	-53.22	37.11	48.26	63.71
Diluted EPS	10.53	-53.22	37.10	48.24	63.69
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	0.0	532.7	0.0	0.0	0.0
+ Tax — Discontinued Operations	0.0	135.4	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	64.2	414.4	353.5
+ Items NOT to be Reclassified to P&L	16.1	-21.9	-12.0	-9.4	-9.5
+ Tax on Items NOT to be Reclassified	—	—	-3.8	2.4	2.4
+ Tax on Items NOT to be Reclassified — alt tag	2.2	-4.3	—	—	—
+ Items to be Reclassified to P&L	185.0	-39.9	86.7	483.2	426.5
+ Tax on Items to be Reclassified	—	—	14.4	57.1	61.1
+ Tax on Items to be Reclassified — alt tag	45.2	8.0	—	—	—
Comprehensive Income — Owners of Parent	—	-1,566.3	1,111.3	0.1	1,661.3
Comprehensive Income — Non-controlling Interests	—	67.2	0.0	1,776.3	490.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	10.53	-67.30	37.11	48.26	63.71
Diluted EPS — Continuing Operations	10.53	-67.30	37.10	48.24	63.69
Basic EPS — Discontinued Operations	0.00	14.08	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	0.00	14.08	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	8,453.2	7,399.7	8,968.4	12,235.0	12,758.9
Gross Margin %	65.07	62.64	67.32	72.04	71.94
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1,634.3	937.5	1,772.0	4,250.8	4,475.4
− Exceptional Items (reconciliation)	-765.9	-901.0	-372.8	-2,266.1	-1,942.9
Net Income Adj (tax-effected)	710.2	-1,073.1	1,326.2	2,917.0	3,177.0
EPS Adj	19.82	-39.84	47.00	103.36	112.59
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	28.2	28.2	28.2	28.2	28.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.